E-viri
PDF
Recenzirano
Odprti dostop
-
De Benedetti, Fabrizio; Gattorno, Marco; Anton, Jordi; Ben-Chetrit, Eldad; Frenkel, Joost; Hoffman, Hal M; Koné-Paut, Isabelle; Lachmann, Helen J; Ozen, Seza; Simon, Anna; Zeft, Andrew; Calvo Penades, Inmaculada; Moutschen, Michel; Quartier, Pierre; Kasapcopur, Ozgur; Shcherbina, Anna; Hofer, Michael; Hashkes, Philip J; Van der Hilst, Jeroen; Hara, Ryoki; Bujan-Rivas, Segundo; Constantin, Tamas; Gul, Ahmet; Livneh, Avi; Brogan, Paul; Cattalini, Marco; Obici, Laura; Lheritier, Karine; Speziale, Antonio; Junge, Guido
The New England journal of medicine, 05/2018, Letnik: 378, Številka: 20Journal Article, Web Resource
The anti–interleukin-1 antibody canakinumab was effective at controlling and preventing recurrence of flares in autoimmune inflammatory diseases: familial Mediterranean fever, mevalonate kinase deficiency, and the TNF receptor–associated periodic syndrome.
